Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form – Particulate form
Reexamination Certificate
1999-12-21
2004-07-13
Carlson, Karen Cochrane (Department: 1653)
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
Particulate form
C424S043000, C424S045000, C424S499000, C424S400000, C424S501000, C514S002600, C514S003100, C530S303000, C530S350000, C530S304000, C530S418000, C426S425000, C426S426000, C426S330000
Reexamination Certificate
active
06761909
ABSTRACT:
FIELD OF THE INVENTION
The invention involves particulate insulin-containing products useful for pulmonary delivery applications, manufacture of insulin-containing particles using compressed anti-solvent precipitation, inhalers actuatable to produce aerosols including insulin-containing particles. In one aspect, the insulin-containing particles are multi-component particulate particles including insulin and a biocompatible polymer useful for sustained release applications.
BACKGROUND OF THE INVENTION
Recently, there has been significant interest in pulmonary delivery of a variety of drugs to subjects via inhalation of aerosolized drug powders.
One important consideration for pulmonary delivery is that small particles in a narrow range of aerodynamic diameters of from about 1 micron to about 5 microns appear to be most effective for deposition in the lungs in a manner to contribute to drug delivery. Larger particles tend to become lodged in the throat during inhalation and smaller particles tend to be exhaled without depositing in the lungs. Because it is difficult to manufacture powder batches restricted to the desired particle size, significant losses of drugs are often experienced during administration to a subject, due to the presence of large quantities of excessively large and/or excessively small particles. Another important consideration is that handling the drug micro-powders during dose measurement and packaging is difficult, because of the small size and often cohesive nature of the particles. Significant quantities of powder can be lost during these handling operations. Significant powder losses can also occur during aerosolization of the powder to produce an aerosol for inhalation by a subject. For example, a dry powder inhaler is typically used to aerosolize a dry powder for inhalation. Significant powder losses in a dry powder inhaler can be caused by poor dispersability of the powder due to interparticulate cohesive forces and by particles coating interior surfaces of the inhaler. The cumulative losses can be large due to combined losses from powder handling, aerosolization and less than optimum particle size and size distribution characteristics. Moreover, if the powder has poor dispersability characteristics, then the aerosol may include a significant quantity of large aggregates that are too large for effective deposition in the lungs. The result is that often only a small percentage of a batch of powder originally manufactured for pulmonary delivery is ultimately delivered to the lungs of a subject. Some of these losses can be reduced through careful design of handling operations and careful design of inhalers to promote satisfactory aerosolization. Losses could further be reduced, however, through manufacture of powders having improved particle size and size distribution characteristics, improved flowability for ease of handling and/or improved dispersability for ease of aerosolization.
One drug that has received considerable attention for pulmonary delivery is insulin. Techniques that have been proposed for preparing insulin powders for pulmonary delivery include spray drying, solvent extraction and jet milling of lyophilized insulin. One problem with spray drying, however, is that the insulin is subjected to high temperatures, which can significantly degrade the insulin and may impair its activity. With solvent extraction techniques, there are often significant problems associated with contamination of powders by residual solvents and surfactants used during the manufacturing operation. The presence of these residual contaminants is undesirable. Jet milling can damage the biological activity of the insulin. Also, the characteristics of powders produced by spray drying, solvent extraction and jet milling could be improved to reduce losses during powder handling and aerosolization and to improve delivery of the aerosolized powder to a subject's lungs.
Another method that has been proposed for manufacturing insulin powders is to precipitate insulin from solution by contacting the solution with an anti-solvent fluid under supercritical conditions. Some references discussing supercritical anti-solvent precipitation of insulin include: Yeo, Sang-Do, et al., “Formation of Microparticulate Protein Powders Using a Supercritical Fluid Antisolvent,” Biotechnology and Bioengineering, Vol. 41, pp. 341-346 (1993); Yeo, Sang-Do, et al., “Secondary Structure Characterization of Microparticulate Insulin Powders,” J. Pharmaceutical Sciences, Vol. 83, No. 12, pp. 1651-1656 (1994); Winters, Michael A., et al., “Precipitation of Proteins in Supercritical Carbon Dioxide,” J. Pharmaceutical Sciences, Vol. 85, No. 6, pp. 586-594 (1996); Winters, Michael A., et al., “Long-Term and High-Temperature Storage of Supercritically-Processed Microparticulate Protein Powders,” Pharmaceutical Research, Vol. 14, No. 10, pp. 1370-1378 (1997); and European Patent No. 0 542 314.
The supercritical anti-solvent precipitation technique has the advantages of producing insulin powders with very little, if any, residual solvent contamination without subjecting the insulin to a high temperature. The noted references, however, are primarily focused on supercritical anti-solvent precipitation of insulin powders for use in applications other than pulmonary delivery, such as subcutaneous applications, and do not discuss processing techniques specifically designed to produce powders with characteristics that are advantageous for pulmonary delivery applications.
There is a significant need for improved techniques to prepare insulin powders for pulmonary delivery applications and for insulin powders with improved powder characteristics for pulmonary delivery applications.
SUMMARY OF THE INVENTION
With the present invention, it has been found that powders often having improved characteristics for pulmonary delivery applications are manufacturable by compressed anti-solvent precipitation when the insulin is processed in a feed solution including the insulin in a cosolvent system including two or more mutually soluble organic solvents.
Therefore, in one aspect the present invention provides a method of making insulin-containing powders in which a feed solution including the insulin in such a cosolvent system is contacted with a compressed anti-solvent fluid, typically compressed carbon dioxide in a near critical or supercritical state, to precipitate insulin-containing particles that are then separated from the anti-solvent fluid. The cosolvent system includes at least a first organic solvent and a second organic solvent, although additional organic solvents may be included as desired for a particular application. The first organic in the cosolvent system is typically a significantly better solvent for insulin and the second organic solvent typically significantly enhances processing to promote preparation of high quality powders for pulmonary delivery applications. As a further possible refinement, it is typically preferred that the cosolvent system include less than about 50% by weight of the first organic solvent.
It has been found that prior supercritical anti-solvent techniques that describe use of a single solvent system for insulin manufacture, typically either DMSO or DMFA as the sole solvent, do not produce powders with sufficiently good flowability or dispersability characteristics to be advantageous for pulmonary delivery. Processing according to the method of the present invention, however, often results in significantly enhanced flowability and/or dispersability of the powders. As a possible refinement on the present invention, it has further been found that the cosolvent system should preferably be substantially organic in nature, meaning that it should be substantially free of water. Although at first blush it might seem that the presence of some water in the cosolvent system would stabilize the insulin during processing, it has been found that the presence of water in the cosolvent system is highly detrimental to flowability and/or dispersability characteristics of the manufactured powder
Carlson Karen Cochrane
Liu Samuel Wei
Marsh & Fischmann & Breyfogle LLP
RxKinetix, Inc.
LandOfFree
Particulate insulin-containing products and method of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Particulate insulin-containing products and method of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Particulate insulin-containing products and method of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3229386